In my life one of the phrases that I use with my family. There are - - PDF document

in my life one of the phrases that i use with my family
SMART_READER_LITE
LIVE PREVIEW

In my life one of the phrases that I use with my family. There are - - PDF document

In my life one of the phrases that I use with my family. There are no crisis unless there are no blood components in the blood bank. Exsanguination is my idea of an emergency. After 41 years in high acuity nursing I find that is is a true


slide-1
SLIDE 1

In my life one of the phrases that I use with my family. There are no crisis unless there are no blood components in the blood bank. Exsanguination is my idea of an emergency. After 41 years in high acuity nursing I find that is is a true statement – but as our knowledge of diseases and the interplay of anticoagulation/thrombosis have grown- I find that I long for better switches to turn anticoagulation and clotting off and on. This presentation is a review of some of the many variables that the reasonable and prudent nurse needs to review in

1

slide-2
SLIDE 2

the Perianesthesia arena.

1

slide-3
SLIDE 3

I will be clear to speak to on and off label uses of medication.

2

slide-4
SLIDE 4

Take away points for you as you walk away from this presentation.

3

slide-5
SLIDE 5

Evidence Based Practice And Practice Based Evidence.

4

slide-6
SLIDE 6

98% of the time we want the tilt of anticoagulation so that blood will flow and carry the nutrients and by products of cellular metabolism But when there is a need for procedural intervention we need wisdom to know how to taper, stop, or continue the disruption of the coagulation cascade.

5

slide-7
SLIDE 7

Which patients are now on direct acting inhibitors, vitamin K warfarin products and or antiplatelet medications is to be about 40% of persons over 50 years of age Guidelines and standards of practice for endovascular and vascular surgery advocate the use of these mediations.

6

slide-8
SLIDE 8

Like any medication genetic component of pharmacogenetics is the the most powerful variable in Absorption, Distribution, Metabolism and Excretion FDA trials don’t have the numeracy to predict all the possible genetic variants with the person/ drug interaction Protein C- PROC Protein S- PROC 1 gene Factor V Leiden- F5 on chromosome one Autoimmune disease therapies Antiphospholipid syndrome and Lupus create

7

slide-9
SLIDE 9

situations that cause intrinsic cascade activation Protonics versus Genomics.

7

slide-10
SLIDE 10

The warnings and black boxes of these medications Which must be pondered

8

slide-11
SLIDE 11

When you are considering the dose and intervals

  • f medications in an urgent / emergent case.

This can be helpful predictor of how much trouble you are in…

9

slide-12
SLIDE 12

Arterial side triad that changes the forces that promote clot are trauma- platelets are typically the first responder Intrinsic aspect Venous side is stasis and that is force with greatest is viscosity so DOAC’s and Warfarin Common Pathway or Extrinsic

10

slide-13
SLIDE 13

When you are taking that home medications list these clinically relevant drug interactions.

11

slide-14
SLIDE 14

Most common medication to see on your list… Aspirin Each category works in a different way and has increasing potency. Clodigrel Turns off platelets for their 7 day life .

12

slide-15
SLIDE 15

Platlet transfusions

13

slide-16
SLIDE 16

Don’t forget these pharmacogenomics issues.

14

slide-17
SLIDE 17

Resting Adhesion Activation Aggregation

15

slide-18
SLIDE 18

Resting Adhesion Activation Aggregation 16

slide-19
SLIDE 19

Resting Adhesion Activation Aggregation 17

slide-20
SLIDE 20

Resting Adhesion Activation Aggregation 18

slide-21
SLIDE 21

Know what your laboratory go to tests for platelet function are and recognize your dialysis patients have dysfunctional platelets.

19

slide-22
SLIDE 22

Resting Adhesion Activation Aggregation 20

slide-23
SLIDE 23

6.5 million folks have atrial fibrillation in the US 2016 numbers

21

slide-24
SLIDE 24

Dabigatran is competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot- bound thrombin, and thrombin-induced platelet aggregation are inhibited. 22

slide-25
SLIDE 25

RAXBIND specifically binds to dabigatran and its acylglucuronide metabolites, neutralizing their anticoagulant effect immediately after administration Binds with higher affinity than dabigatran to thrombin Has no effect on other anticoagulant or antithrombotic therapies Immunogenicity Low potential for immune reactions 4% of volunteers showed low concentrations of treatment-emergent antibodies that may persist Angioedema is always a problem with monoclonal events

23

slide-26
SLIDE 26

Checklists for pondering Consistent to help you think through Especially helpful with elective cases

24

slide-27
SLIDE 27

Xarelto Rivaroxaban is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.

25

slide-28
SLIDE 28

Apixaban ( Eliquis) inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.

26

slide-29
SLIDE 29

Edoxaban Savaysa is a Factor Xa inhibitor. This medication requires calculation of creatinine clearance for optimal outcomes and has a black box warning about renal function.

27

slide-30
SLIDE 30

Pondering Points

28

slide-31
SLIDE 31

Atrial Fibrillation stroke risk

29

slide-32
SLIDE 32

Change them from long acting warfarin to short acting heparin May still be relevant in mechanical heart valve and high risk series

30

slide-33
SLIDE 33

Few Randomized control trials on DOAC and Anti- Platlet discontinuation

31

slide-34
SLIDE 34

Highest risk : OB Neurosurgery Vascular Cardiothraic surgery

32

slide-35
SLIDE 35

Time for Huddle

33

slide-36
SLIDE 36

Risks and Benefits Pacemaker versus Open Heart Surgery

34

slide-37
SLIDE 37

How much trouble am I in?

35

slide-38
SLIDE 38

Practice of each discipline: Nursing, Medicine

36

slide-39
SLIDE 39

Take Away Points Blood Management Process Current article in Critical Care Nurse Blood Flow Versus Cellular Death

37

slide-40
SLIDE 40

All about the Blood

38

slide-41
SLIDE 41

Going anyway>>>>

39

slide-42
SLIDE 42

40

slide-43
SLIDE 43

41

slide-44
SLIDE 44

42

slide-45
SLIDE 45

43

slide-46
SLIDE 46

44

slide-47
SLIDE 47

45

slide-48
SLIDE 48

46

slide-49
SLIDE 49

47

slide-50
SLIDE 50

48

slide-51
SLIDE 51

49

slide-52
SLIDE 52

50